131 related articles for article (PubMed ID: 37615986)
1. Missing Components of Receptor Status Among Women With Invasive Breast Cancer.
Stephens JA; Fisher JL; Wesolowski R; Paskett ED
JAMA Netw Open; 2023 Aug; 6(8):e2330791. PubMed ID: 37615986
[TBL] [Abstract][Full Text] [Related]
2. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Race and Ethnicity-Adjusted Age Recommendation for Initiating Breast Cancer Screening.
Chen T; Kharazmi E; Fallah M
JAMA Netw Open; 2023 Apr; 6(4):e238893. PubMed ID: 37074714
[TBL] [Abstract][Full Text] [Related]
5. Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer.
Khoury T; Mendicino L; Payne Ondracek R; Yao S; Davis W; Omilian AR; Kwan ML; Roh JM; D'Addario L; Valice E; Fernandez D; Ergas IJ; Chua AV; Ambrosone CB; Kushi LH
JAMA Netw Open; 2024 Mar; 7(3):e243345. PubMed ID: 38517439
[TBL] [Abstract][Full Text] [Related]
6. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
Kyalwazi B; Yau C; Campbell MJ; Yoshimatsu TF; Chien AJ; Wallace AM; Forero-Torres A; Pusztai L; Ellis ED; Albain KS; Blaes AH; Haley BB; Boughey JC; Elias AD; Clark AS; Isaacs CJ; Nanda R; Han HS; Yung RL; Tripathy D; Edmiston KK; Viscusi RK; Northfelt DW; Khan QJ; Asare SM; Wilson A; Hirst GL; Lu R; Symmans WF; Yee D; DeMichele AM; van 't Veer LJ; Esserman LJ; Olopade OI
JAMA Netw Open; 2023 Dec; 6(12):e2349646. PubMed ID: 38153734
[TBL] [Abstract][Full Text] [Related]
7. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
Peiffer DS; Zhao F; Chen N; Hahn OM; Nanda R; Olopade OI; Huo D; Howard FM
JAMA Oncol; 2023 Apr; 9(4):500-510. PubMed ID: 36821125
[TBL] [Abstract][Full Text] [Related]
9. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
Howlader N; Altekruse SF; Li CI; Chen VW; Clarke CA; Ries LA; Cronin KA
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777111
[TBL] [Abstract][Full Text] [Related]
10. Historical Redlining, Persistent Mortgage Discrimination, and Race in Breast Cancer Outcomes.
Miller-Kleinhenz JM; Barber LE; Maliniak ML; Moubadder L; Bliss M; Streiff MJ; Switchenko JM; Ward KC; McCullough LE
JAMA Netw Open; 2024 Feb; 7(2):e2356879. PubMed ID: 38376843
[TBL] [Abstract][Full Text] [Related]
11. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.
Iqbal J; Ginsburg O; Rochon PA; Sun P; Narod SA
JAMA; 2015 Jan; 313(2):165-73. PubMed ID: 25585328
[TBL] [Abstract][Full Text] [Related]
12. Disparities in breast cancer characteristics and outcomes by race/ethnicity.
Ooi SL; Martinez ME; Li CI
Breast Cancer Res Treat; 2011 Jun; 127(3):729-38. PubMed ID: 21076864
[TBL] [Abstract][Full Text] [Related]
13. Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race.
Zhou J; Cueto J; Ko NY; Hoskins KF; Nabulsi NA; Asfaw AA; Hubbard CC; Mitra D; Calip GS; Law EH
Breast; 2021 Oct; 59():367-375. PubMed ID: 34419726
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
15. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US.
Shubeck S; Zhao F; Howard FM; Olopade OI; Huo D
JAMA Netw Open; 2023 Mar; 6(3):e235834. PubMed ID: 36995711
[TBL] [Abstract][Full Text] [Related]
16. Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016.
Acheampong T; Kehm RD; Terry MB; Argov EL; Tehranifar P
JAMA Netw Open; 2020 Aug; 3(8):e2013226. PubMed ID: 32804214
[TBL] [Abstract][Full Text] [Related]
17. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Hoskins KF; Danciu OC; Ko NY; Calip GS
JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
[TBL] [Abstract][Full Text] [Related]
18. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.
; Mavaddat N; Dorling L; Carvalho S; Allen J; González-Neira A; Keeman R; Bolla MK; Dennis J; Wang Q; Ahearn TU; Andrulis IL; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Briceno I; Brüning T; Camp NJ; Campbell A; Castelao JE; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Christiansen H; Czene K; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; Geisler J; Giles GG; Guénel P; Hadjisavvas A; Hahnen E; Hall P; Hamann U; Hartikainen JM; Hartman M; Hoppe R; Howell A; Jakubowska A; Jung A; Khusnutdinova EK; Kristensen VN; Li J; Lim SH; Lindblom A; Loizidou MA; Lophatananon A; Lubinski J; Madsen MJ; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Milne RL; Mohd Taib NA; Morra A; Muir K; Obi N; Osorio A; Park-Simon TW; Peterlongo P; Radice P; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Sim X; Southey MC; Thorne H; Tomlinson I; Torres D; Truong T; Yip CH; Spurdle AB; Vreeswijk MPG; Dunning AM; García-Closas M; Pharoah PDP; Kvist A; Muranen TA; Nevanlinna H; Teo SH; Devilee P; Schmidt MK; Easton DF
JAMA Oncol; 2022 Mar; 8(3):e216744. PubMed ID: 35084436
[TBL] [Abstract][Full Text] [Related]
19. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
20. Association of Insurance Status and Racial Disparities With the Detection of Early-Stage Breast Cancer.
Ko NY; Hong S; Winn RA; Calip GS
JAMA Oncol; 2020 Mar; 6(3):385-392. PubMed ID: 31917398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
